2023
Patient Preferences for Postmastectomy Breast Reconstruction
Shammas R, Hung A, Mullikin A, Sergesketter A, Lee C, Reed S, Fish L, Greenup R, Hollenbeck S. Patient Preferences for Postmastectomy Breast Reconstruction. JAMA Surgery 2023, 158: 1285-1292. PMID: 37755818, PMCID: PMC10535024, DOI: 10.1001/jamasurg.2023.4432.Peer-Reviewed Original ResearchConceptsRisk of complicationsBreast reconstructionAbdominal morbidityFlap reconstructionBreast cancerGenetic predispositionPatient-physician discussionsImplant-based reconstructionPostmastectomy breast reconstructionCross-sectional studyChance of complicationsPatient-centered careAdditional operationsHigher educational levelMajor complicationsPreoperative counselingPatient preferencesFlap appearanceTreatment preferencesImplant reconstructionMAIN OUTCOMENew diagnosisPatient valuesComplicationsMean increaseWhere Are the Children? A Thematic Analysis of State, Territory, and Tribal Organization Comprehensive Cancer Control Plans
Leraas H, Beckhorn C, Washabaugh C, Thamby J, Greenup R, Haines K, Allen L, Tracy E. Where Are the Children? A Thematic Analysis of State, Territory, and Tribal Organization Comprehensive Cancer Control Plans. Journal Of Pediatric Surgery 2023, 59: 129-133. PMID: 37858391, DOI: 10.1016/j.jpedsurg.2023.09.022.Peer-Reviewed Original ResearchConceptsComprehensive Cancer Control ProgramPediatric cancer careCancer careChildhood cancerEarly detectionPediatric cancer survivorshipComprehensive cancer control plansDistrict of ColumbiaCancer control programsCancer control plansAdult cancer riskU.S. territoriesTreatment disparitiesPediatric oncologyRisk factorsCancer preventionLevel IVCancer survivorshipCancer riskPediatric cancerChildhood exposureCancerCancer treatmentCareTribal organizationsDefining Priorities in Value-Based Cancer Care: Insights From the Alliance for Clinical Trials in Oncology National Cooperative Group Survey
Allen C, Snyder R, Horn D, Hudson M, Barber A, Smieliauskas F, Spears P, Edge S, Greenup R. Defining Priorities in Value-Based Cancer Care: Insights From the Alliance for Clinical Trials in Oncology National Cooperative Group Survey. JCO Oncology Practice 2023, 19: 932-938. PMID: 37651652, PMCID: PMC10615548, DOI: 10.1200/op.23.00159.Peer-Reviewed Original ResearchConceptsPatient-reported outcomesInclusion of PROsQuality of lifePatients' QOLClinical trialsHealth care systemHealth system performanceCancer CenterCancer-related health care costsCare systemTherapeutic assessmentAcademic cancer centerEvidence-based careCancer clinical trialsDirect patient careHealth care costsNational Cancer InstituteOncologic outcomesOverall survivalMedical oncologistsCancer careOncology practiceCancer InstituteNonphysician providersCare costsUsing Crowdfunding Campaigns to Examine Financial Toxicity and Logistical Burdens Facing Families of Children With Wilms Tumor
Leraas H, Moya-Mendez M, Donohue V, Kawano B, Olson L, Sekar A, Robles J, Wagner L, Greenup R, Haines K, Tracy E. Using Crowdfunding Campaigns to Examine Financial Toxicity and Logistical Burdens Facing Families of Children With Wilms Tumor. Journal Of Surgical Research 2023, 291: 640-645. PMID: 37542779, DOI: 10.1016/j.jss.2023.07.005.Peer-Reviewed Original ResearchRelative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US
Kc M, Fan J, Hyslop T, Hassan S, Cecchini M, Wang S, Silber A, Leapman M, Leeds I, Wheeler S, Spees L, Gross C, Lustberg M, Greenup R, Justice A, Oeffinger K, Dinan M. Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US. JAMA Network Open 2023, 6: e2323115. PMID: 37436746, PMCID: PMC10339147, DOI: 10.1001/jamanetworkopen.2023.23115.Peer-Reviewed Original ResearchConceptsLong-term survivorsCancer-specific mortalityColorectal cancerCancer cohortReceptor statusInitial diagnosisGleason scoreProstate cancerBreast cancerLong-term adult survivorsMedian cancer-specific survivalEnd Results cancer registryProstate-specific antigen levelRectal cancer cohortCancer-specific survivalStage III diseaseYear of diagnosisProgesterone receptor statusEstrogen receptor statusProportion of deathsSurvival time ratioEarly-stage cancerNononcologic outcomesIndex cancerLocalized diseaseAncillary Treatment Referrals and Visits After Breast Cancer Surgery in a Sociodemographically Diverse Population
Chan V, Heller D, Berger E, Capozza S, Greenup R, Sanft T. Ancillary Treatment Referrals and Visits After Breast Cancer Surgery in a Sociodemographically Diverse Population. Annals Of Surgical Oncology 2023, 30: 5637-5648. PMID: 37266804, DOI: 10.1245/s10434-023-13431-5.Peer-Reviewed Original ResearchConceptsBreast cancer surgeryHealth care accessCancer surgeryMultivariable analysisAncillary treatmentHigher median household incomeHispanic ethnicityCare accessYale New Haven Health SystemBreast cancer surgical patientsPoor health care accessMedian household incomeEnd pointMultivariable logistic regression analysisHealth systemHigh school degreeCancer surgical patientsPrimary end pointLogistic regression analysisUrban cancer centerPostoperative referralPostoperative morbidityAdjunctive therapyProvider referralSurgical patientsMultidimensional financial hardship among uninsured and insured young adult patients with metastatic breast cancer
Wheeler S, Spencer J, Manning M, Samuel C, Reeder‐Hayes K, Greenup R, Spees L, Rosenstein D. Multidimensional financial hardship among uninsured and insured young adult patients with metastatic breast cancer. Cancer Medicine 2023, 12: 11930-11940. PMID: 37148550, PMCID: PMC10242847, DOI: 10.1002/cam4.5885.Peer-Reviewed Original ResearchImplementation of an educational intervention to improve medical student cost awareness: a prospective cohort study
Tait S, Oshima S, Leeras H, Gunn A, Sarver M, Gunes F, Greenup R. Implementation of an educational intervention to improve medical student cost awareness: a prospective cohort study. BMC Medical Education 2023, 23: 73. PMID: 36717888, PMCID: PMC9885673, DOI: 10.1186/s12909-023-04038-1.Peer-Reviewed Original ResearchConceptsProspective cohort studyPost-intervention surveysCost-conscious careCohort studyHigh-value careIntervention armMedical students' knowledgeEducational interventionNon-intervention armPre-intervention responsesCost awarenessFinancial hardshipSelf-reported preparednessMajority of participantsStudents' knowledgePatient costsTreatment decisionsHealthcare costsCare practicesLatter cohortModifiable Barriers and Facilitators for Breast Cancer Care: A Thematic Analysis of Patient and Provider Perspectives
Fayanju O, Greenup R, Zafar S, Hyslop T, Hwang E, Fish L. Modifiable Barriers and Facilitators for Breast Cancer Care: A Thematic Analysis of Patient and Provider Perspectives. Journal Of Surgical Research 2023, 284: 269-279. PMID: 36610386, PMCID: PMC10020986, DOI: 10.1016/j.jss.2022.11.074.Peer-Reviewed Original ResearchConceptsBreast cancer treatmentBreast cancerModifiable barriersCancer treatmentProvider perspectivesSurgical oncology careBreast cancer careAdvanced practice providersSingle health systemModifiable contributorOncologic careModifiable factorsOncology careCancer careTreatment receiptPatients' perceptionsStage 0Practice providersCare receiptPatientsExemplar quotesThematic analysisSuboptimal communicationHealth systemTreatment costs
2022
Genetic testing in privately insured women with surgically treated breast cancer
Dinan M, Pitafi S, Greenup R, Long J, Gross C. Genetic testing in privately insured women with surgically treated breast cancer. Breast Cancer Research And Treatment 2022, 198: 177-181. PMID: 36542252, DOI: 10.1007/s10549-022-06829-4.Peer-Reviewed Original ResearchConceptsBreast cancerGenetic testingRoutine breast cancer careBRCA1/BRCA2 genetic testingHormone receptor statusBreast cancer careInvasive breast cancerBRCA2 genetic testingReceptor statusWomen 50Cancer careAge 45Family historyOlder womenInsurer databaseYoung womenCancerWomenCoverage policiesUnclear implicationsPatientsSurgeryPurposeRatesYearsPrevalenceModifiable patient-reported factors associated with cancer-screening knowledge and participation in a community-based health assessment
Fayanju O, Oyekunle T, Thomas S, Ingraham K, Fish L, Greenup R, Oeffinger K, Zafar S, Hyslop T, Hwang E, Patierno S, Barrett N. Modifiable patient-reported factors associated with cancer-screening knowledge and participation in a community-based health assessment. The American Journal Of Surgery 2022, 225: 617-629. PMID: 36411107, PMCID: PMC10085670, DOI: 10.1016/j.amjsurg.2022.10.059.Peer-Reviewed Original ResearchConceptsColorectal cancer screeningModifiable factorsCancer screeningGuideline-concordant screeningPatient-reported factorsHealthy dietary habitsHealth assessmentCommunity-based sampleColorectal screeningColorectal cancerDietary habitsDisease preventionMedical careBehavioral interventionsLess breastBreastLifestyle choicesCentral North CarolinaProstateCancerScreeningCommunity eventsGreater knowledgeFactorsNegative attitudesTreatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021
Chehayeb R, Hood A, Wang X, Miksad R, Mougalian S, Lustberg M, Wang S, Greenup R, Pusztai L, Kunst N. Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021. JAMA Network Open 2022, 5: e2244204. PMID: 36445704, PMCID: PMC9709649, DOI: 10.1001/jamanetworkopen.2022.44204.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerErbB2-positive metastatic breast cancerHR-positive metastatic breast cancerLines of therapyMBC subtypesDrug costsBreast cancerMedical costsHuman epidermal growth factor receptor 2 receptor statusMBC treatmentERBB2-negative metastatic breast cancerAssociated direct medical costsEarly-stage breast cancerHormone receptorsFlatiron Health databaseMetastatic recurrence ratesDifferent drug regimensBreast cancer careData of patientsDirect medical costsNovel adjuvant therapySupportive care drugsOutcomes of interestCost-effectiveness analysisAdjuvant therapy
2020
Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis
Spring L, Fell G, Arfe A, Sharma C, Greenup R, Reynolds K, Smith B, Alexander B, Moy B, Isakoff S, Parmigiani G, Trippa L, Bardia A. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clinical Cancer Research 2020, 26: 2838-2848. PMID: 32046998, PMCID: PMC7299787, DOI: 10.1158/1078-0432.ccr-19-3492.Peer-Reviewed Original ResearchConceptsPathologic complete responseEvent-free survivalBetter event-free survivalNeoadjuvant chemotherapyAdjuvant chemotherapyOverall survivalComplete responseBreast cancerImproved event-free survivalIndividual patient-level dataAdditional adjuvant therapySubsequent adjuvant chemotherapyBreast cancer recurrencePatient-level dataComprehensive Meta-AnalysisAdjuvant settingNeoadjuvant responseAdjuvant therapyMicrometastatic diseaseImproved survivalPrognostic significanceSystemic clearanceCancer recurrenceInclusion criteriaChemotherapy
2019
Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma
Thornton M, Williamson H, Westbrook K, Greenup R, Plichta J, Rosenberger L, Gupta A, Hyslop T, Hwang E, Fayanju O. Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma. Annals Of Surgical Oncology 2019, 26: 3166-3177. PMID: 31342392, PMCID: PMC6736696, DOI: 10.1245/s10434-019-07564-9.Peer-Reviewed Original ResearchConceptsNeoadjuvant endocrine therapyInvasive lobular carcinomaOverall survivalEndocrine therapyLobular carcinomaHormone receptor-positive groupNational Cancer Data BaseLower ratesPathologic complete responseKaplan-Meier curvesReceptor-positive groupCox proportional hazardsBackgroundNeoadjuvant chemotherapyCN1-3More comorbiditiesPostmastectomy radiationNeoadjuvant chemotherapyNeoadjuvant therapyComplete responseClinical trialsBreast cancerCT classificationSmall tumorsProportional hazardsGreater burden
2018
The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT)
Fayanju O, Ren Y, Thomas S, Greenup R, Plichta J, Rosenberger L, Tamirisa N, Force J, Boughey J, Hyslop T, Hwang E. The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT). Annals Of Surgery 2018, 268: 591-601. PMID: 30048319, PMCID: PMC6496955, DOI: 10.1097/sla.0000000000002953.Peer-Reviewed Original ResearchConceptsPathologic complete responseImproved overall survivalNeoadjuvant chemotherapyOverall survivalComplete responseBreast cancerHuman epidermal growth factor receptor 2 (HER2) statusEpidermal growth factor receptor 2 statusCox proportional hazards modelHormone receptorsNode-positive patientsTriple-negative diseaseKaplan-Meier curvesBreast cancer patientsMultivariate logistic regressionProportional hazards modelAnatomic extentCancer patientsReceptor subtypesClinical significanceHazards modelTumor subtypesPatientsBreastLogistic regressionAxillary Nodal Evaluation in Elderly Breast Cancer Patients: Potential Effects on Treatment Decisions and Survival
Tamirisa N, Thomas S, Fayanju O, Greenup R, Rosenberger L, Hyslop T, Hwang E, Plichta J. Axillary Nodal Evaluation in Elderly Breast Cancer Patients: Potential Effects on Treatment Decisions and Survival. Annals Of Surgical Oncology 2018, 25: 2890-2898. PMID: 29968029, PMCID: PMC6404232, DOI: 10.1245/s10434-018-6595-2.Peer-Reviewed Original ResearchConceptsBreast cancer patientsElderly breast cancer patientsCN0 breast cancerOverall survivalNodal surgeryCancer patientsAxillary surgeryElderly patientsTreatment decisionsBreast cancerCharlson-Deyo comorbidity scoreCN0 breast cancer patientsSurgical lymph node evaluationCox proportional hazards modelAdjuvant therapy decisionsAdjuvant therapy receiptAxillary nodal evaluationLymph node evaluationNational Cancer DatabaseYear of diagnosisWorse overall survivalEstrogen receptor statusLong-term outcomesSubsequent treatment decisionsProportional hazards modelThe Effect of Hospital Volume on Breast Cancer Mortality
Greenup R, Obeng-Gyasi S, Thomas S, Houck K, Lane W, Blitzblau R, Hyslop T, Hwang E. The Effect of Hospital Volume on Breast Cancer Mortality. Annals Of Surgery 2018, 267: 375-381. PMID: 27893532, PMCID: PMC5994238, DOI: 10.1097/sla.0000000000002095.Peer-Reviewed Original ResearchConceptsHigh-volume centersNational Cancer Data BaseHospital volumeVolume centersBreast cancerHazard ratioImproved survivalStage 0Case volumeMultivariable Cox proportional hazards modelsMultidisciplinary breast cancer treatmentMultivariable Cox proportional hazardsSurgeons National Cancer Data BaseCox proportional hazards modelAnnual hospital volumeLess common cancersUnilateral breast cancerBreast cancer mortalityBreast cancer patientsCubic spline analysisLog-rank testBreast cancer treatmentCox proportional hazardsProportional hazards modelHigher case volumeOncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations: A Multi-institutional Study
Jakub J, Peled A, Gray R, Greenup R, Kiluk J, Sacchini V, McLaughlin S, Tchou J, Vierkant R, Degnim A, Willey S. Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations: A Multi-institutional Study. JAMA Surgery 2018, 153: 123-129. PMID: 28903167, PMCID: PMC5838709, DOI: 10.1001/jamasurg.2017.3422.Peer-Reviewed Original ResearchConceptsProphylactic nipple-sparing mastectomyNipple-sparing mastectomyRisk-reducing mastectomyPrimary breast cancerBRCA mutationsBreast cancerOncologic safetyContralateral risk-reducing mastectomyNew primary breast cancerOccult primary breast cancerCancer risk-reducing strategiesIpsilateral breast cancerNew breast cancersBreast cancer eventsCohort of patientsNipple-sparing mastectomiesPrimary outcome measureBRCA1/2 mutation carriersFree nipple graftSuperior cosmetic outcomesEvidence-based dataHealth care professionalsMulti-institutional studyNipple-areolar complexProphylactic side
2017
The Impact of Autologous Breast Reconstruction on Body Mass Index Patterns in Breast Cancer Patients
Cho E, Shammas R, Glener A, Greenup R, Hwang E, Hollenbeck S. The Impact of Autologous Breast Reconstruction on Body Mass Index Patterns in Breast Cancer Patients. Plastic & Reconstructive Surgery 2017, 140: 1121-1131. PMID: 29176410, DOI: 10.1097/prs.0000000000003841.Peer-Reviewed Original ResearchConceptsBody mass index (BMI) changeAutologous breast reconstructionBody mass index increaseBreast cancer patientsBody mass index (BMI) patternsBreast reconstructionCancer patientsMultivariable regressionNormal baseline body mass indexBaseline body mass indexImmediate autologous breast reconstructionCLINICAL QUESTION/LEVELHigh-risk patientsPropensity-matched pairsBody mass indexRisk of recurrenceWeight management strategiesBaseline obesityAdjuvant therapyTotal patientsMass indexTherapeutic mastectomyMastectomy patientsAutologous reconstructionAuthors' institutionPathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer.
Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R, Coopey S, Taghian A, Hughes K, Isakoff S, Ellisen L, Smith B, Specht M, Moy B, Bardia A. Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer. Journal Of The National Comprehensive Cancer Network 2017, 15: 1216-1223. PMID: 28982747, DOI: 10.6004/jnccn.2017.0158.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsFemaleFollow-Up StudiesHumansMutationNeoadjuvant TherapyNeoplasm GradingNeoplasm StagingRecurrenceRegistriesRetrospective StudiesSurvival AnalysisTreatment OutcomeTriple Negative Breast NeoplasmsYoung AdultConceptsPathologic complete responseDisease-free survivalBaseline clinical stageNeoadjuvant chemotherapyOverall survivalBreast cancerYoung womenComplete responseClinical stageResidual diseaseInvasive breast cancerLong-term outcomesAggressive tumor biologyMassachusetts General HospitalDFS ratesNeoadjuvant therapyOS ratesSurvival outcomesSurrogate markerGeneral HospitalBest therapyHigh riskTrial designRapid triagePatients